Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for moderate to severe nail psoriasis
2012-005413-40Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in nail psoriasis and psoriasis (3 arms), sponsored by Novartis. Primary endpoint: Change in Nail Psoriasis Severity Index at Week 16. Started Mar 2013; status: completed.
02
Drugs
secukinumab
03
Conditions
nail psoriasispsoriasis
Beyond the preview
Go deeper on 2012-005413-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005413-40.